Agios Pharmaceuticals (AGIO) Current Assets (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Current Assets data on file, last reported at $717.7 million in Q2 2026.

• Quarterly Current Assets fell 29.6% year-over-year to $717.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $717.7 million (down 29.6% YoY) and the FY2025 annual result came in at $942.1 million, down 2.44% from the prior year.
• Current Assets fell to $717.7 million in Q2 2026, from $834.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.1 billion in Q3 2024 to a low of $632.1 million in Q2 2024.
• A 5-year average of $855.6 million and a median of $834.3 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets tumbled 58.59% — and 2025, when it soared 61.28%.
• Tracing AGIO's Current Assets over 5 years: stood at $832.8 million in 2022, then gained by 0.13% to $833.8 million in 2023, then climbed by 15.8% to $965.6 million in 2024, then declined by 2.44% to $942.1 million in 2025, then slipped by 23.82% to $717.7 million in 2026.
• The last three Current Assets figures came in at $717.7 million (Q2 2026), $834.8 million (Q1 2026), and $942.1 million (Q4 2025), per Business Quant data.